Codex DNA, Inc. (DNAY)

NASDAQ: DNAY · IEX Real-Time Price · USD
-0.26 (-5.87%)
At close: May 20, 2022 4:00 PM
0.02 (0.48%)
After-hours:May 20, 2022 5:28 PM EDT

Company Description

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.

Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020.

Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Codex DNA, Inc.
CountryUnited States
IPO DateJun 18, 2021
IndustryMedical Devices
SectorHealth Care

Contact Details

9535 Waples Street
San Diego, CA 92121-2993
United States
Phone858 228 4115

Stock Details

Ticker SymbolDNAY
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$16.00
CIK Code1850079

Key Executives

Dr. Todd R. Nelson MBA, Ph.D.President, Chief Operating Officer, Chief Executive Officer and Director
Jennifer Isacoff McNealey M.H.A.Chief Financial Officer
Daniel G. Gibson Ph.D.Chief Technology Officer
Richard LepkeDirector of Investor Relations
Robert H. CutlerChief Legal Officer
Dr. Madoo Varma Ph.D.Vice President of Corporate Business Development
Laura B. Puga M.B.A.Vice President of People and Culture
Decky Goodrich M.B.A.Senior Vice President of Commercial Operations
Laurence WardenSenior Vice President of Engineering and Instrumentation
Dimas Jimenez M.B.A.Vice President and Corporate Controller

Latest SEC Filings

May 10, 202210-QQuarterly report [Sections 13 or 15(d)]
May 10, 20228-KCurrent report
Apr 29, 2022DEF 14AOther definitive proxy statements
Mar 23, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 23, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 22, 20228-KCurrent report
Mar 1, 20224Statement of changes in beneficial ownership of securities
Mar 1, 20224Statement of changes in beneficial ownership of securities
Mar 1, 20224Statement of changes in beneficial ownership of securities
Mar 1, 20224Statement of changes in beneficial ownership of securities
View All SEC Filings